Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Yada KanjanapanSheau Wen LokPeter GibbsRichard De BoerBelinda YeoSally GreenbergFrances BarnettLouise KnottGary RichardsonRachel WongMichelle NottageIan M CollinsJavier TorresJanine LombardJulie JohnsMichael HaroldLaeeq MalikPublished in: Breast cancer research and treatment (2020)
Prior receipt of NAT was associated with inferior median PFS following first-line HER2-based therapy in the metastatic setting. However, prior NAT exposure did not significantly impact OS, supporting the efficacy of taxane, trastuzumab, pertuzumab combination for first-line HER2+ MBC regardless of prior NAT exposure. Patients with de novo MBC had the longest survival, suggesting stratification for synchronous versus metachronous disease in prospective clinical trials of MBC should be considered.